PePediatric Migraine Clinical Trial
Biohaven Pharmaceuticals is studying an investigational drug, called rimegepant, for the acute treatment of migraines in the pediatric population. If you or your child, between 12 and 18 years of age, suffer from migraine for at least 6 months you may qualify. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided.
Who is this study for?
You may qualify for this study if you meet the following criteria:
You are between the ages of 12 and 18 years of age.
You must have at least 1 migraine per month
The migraine study clinicians will further assess your medical and migraine history to determine your eligibility.
You may receive:
Study-related evaluations of your migraine-related symptoms and overall health.*
You may receive compensation for participation.
*You do not need insurance to participate.
What is a Clinical Trial?
Before a medication can be approved for treatment, the FDA requires that it be tested in a clinical trial, also known as a clinical study, to evaluate the safety and effectiveness of the drug.
Clinical trials take place in medical centers around the world, and involve volunteers helping doctors look at new ways to treat conditions.
Clinical trials represent the latest research about your condition and may offer new treatment options.
Click the button below to see if you qualify for this study: